Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects

Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis

Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914 · see citing works

Biochemical, physiological and medical aspects of ubiquinone function

Ernster, L., & Dallner, G. (1995) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/0925-4439(95)00028-3 · Cited by 1,232 · see citing works

Abnormalities of the electron transport chain in idiopathic parkinson's disease

Parker, W. D., Boyson, S. J., & Parks, J. K. (1989) · Annals of Neurology · doi:10.1002/ana.410260606 · Cited by 1,061 · see citing works

The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it

Fahn, S., & Cohen, G. (1992) · Annals of Neurology · doi:10.1002/ana.410320616 · Cited by 927 · see citing works

Oxygen radicals and the nervous system

Halliwell, B. B., & Gutteridge, J. M. C. (1985) · Trends in Neurosciences · doi:10.1016/0166-2236(85)90010-4 · Cited by 822 · see citing works

Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease

Schapira, A. H. V., Mann, V. M., Cooper, J. A. D., Dexter, D. T., Daniel, S. E., Jenner, P. G., Clark, J. B., & MARSDEN, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb05809.x · Cited by 673 · see citing works

Low platelet mitochondrial complex I and complex II/III activity in early untreated parkinson's disease

Haas, R. H., Nasirian, F., Nakano, K., Ward, D., Pay, M., Hill, R., & Shults, C. W. (1995) · Annals of Neurology · doi:10.1002/ana.410370604 · Cited by 435 · see citing works

Lovastatin decreases coenzyme Q levels in humans.

Folkers, K., Langsjoen, P. H., Willis, R. A., Richardson, P. C., Xia, L., Ye, C. Q., & Tamagawa, H. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.22.8931 · Cited by 426 · see citing works

Platelet mitochondria function in Parkinson's disease

Krige, D., Carroll, M. T., Cooper, J. A. D., MARSDEN, C. D., & Schapira, A. H. V. (1992) · Annals of Neurology · doi:10.1002/ana.410320612 · Cited by 358 · see citing works

Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes

Benecke, R., Strumper, P., & Weiss, H. (1993) · Brain · doi:10.1093/brain/116.6.1451 · Cited by 220 · see citing works

Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease

Janetzky, B., Hauck, S., Youdim, M. B. H., Riederer, P. F., Jellinger, K. A., Pantucek, F., ̈chling, R. Z., Boissl, K. W., & Reichmann, H. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90372-7 · Cited by 206 · see citing works

Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease

Yoshino, H., Nakagawa-Hattori, Y., Kondo, T., & Mizuno, Y. (1992) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02257619 · Cited by 195 · see citing works

Biomedical and Clinical Aspects of Coenzyme Q

Goodwin, T. W. (1977) · FEBS Letters · doi:10.1016/0014-5793(77)80678-9 · Cited by 132 · see citing works

Biochemical mechanism of action of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)

Sayre, L. M. (1989) · Toxicology Letters · doi:10.1016/0378-4274(89)90168-9 · Cited by 115 · see citing works

Idebenone improves cerebral mitochondrial oxidative metabolism in a patient with MELAS

Ikejiri, Y., Mori, E., Ishii, K., Nishimoto, K., Yasuda, M., & Sasaki, M. (1996) · Neurology · doi:10.1212/wnl.47.2.583 · Cited by 72 · see citing works

The Role of Oxidative Stress in Parkinson's Disease

Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845 · see citing works

Role of Free Radicals in the Neurodegenerative Diseases: Therapeutic Implications for Antioxidant Treatment

Halliwell, B. (2001) · Drugs & Aging · doi:10.2165/00002512-200118090-00004 · Cited by 1,502 · see citing works

Metabolism and function of coenzyme Q

Turunen, M., Olsson, J., & Dallner, G. (2004) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2003.11.012 · Cited by 1,026 · see citing works

International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's disease

Fox, S. H., Katzenschlager, R., Lim, S., Barton, B. R., de Bie, R. M. A., Seppi, K., Coelho, M. M., & Sampaio, C. (2018) · Movement Disorders · doi:10.1002/mds.27372 · Cited by 1,009 · see citing works

Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline

Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984 · see citing works

Expression of Nrf2 in Neurodegenerative Diseases

Ramsey, C. P., Glass, C. A., Montgomery, M. B., Lindl, K. A., Ritson, G. P., Chia, L. A., Hamilton, R. L., Chu, C. T., & Jordan-Sciutto, K. L. (2007) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/nen.0b013e31802d6da9 · Cited by 760 · see citing works

Idiopathic hyposmia as a preclinical sign of Parkinson's disease

Ponsen, M. M., Stoffers, D., Booij, J., van Eck‐Smit, B. L. F., Wolters, E. C., & Berendse, H. W. (2004) · Annals of Neurology · doi:10.1002/ana.20160 · Cited by 741 · see citing works

Experimental models of Parkinson's disease

Beal, M. F. (2001) · Nature reviews. Neuroscience · doi:10.1038/35072550 · Cited by 634 · see citing works

A double‐blind, placebo‐controlled study to assess the mitochondria‐targeted antioxidant MitoQ as a disease‐modifying therapy in Parkinson's disease

Snow, B. J., Rolfe, F. L., Lockhart, M. M., Frampton, C. M., O'Sullivan, J. D., Fung, V., Smith, R. A. J., Murphy, M. P., Taylor, K. M., & On behalf of the Protect Study Group (2010) · Movement Disorders · doi:10.1002/mds.23148 · Cited by 606 · see citing works

Coenzyme Q ₁₀ administration increases brain mitochondrial concentrations and exerts neuroprotective effects

Matthews, R. T., Yang, L., Browne, S., Baik, M., & Beal, M. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8892 · Cited by 557 · see citing works

Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease

Beal, M. F. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07470.x · Cited by 523 · see citing works

Oxidative Stress in Parkinson's Disease

Zhou, C. H., Huang, Y., & Przedborski, S. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.023 · Cited by 453 · see citing works

A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease

The Parkinson Study Group QE3 Investigators, Beal, M. F., Oakes, D., Shoulson, I., Henchcliffe, C., Galpern, W. R., Haas, R., Juncos, J. L., Nutt, J. G., Voss, T., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.131 · Cited by 410 · see citing works

Mitochondria in Neurodegeneration: Acute Ischemia and Chronic Neurodegenerative Diseases

Fiskum, G. M., Murphy, A. N., & Beal, M. F. (1999) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199904000-00001 · Cited by 351 · see citing works

The Role of Oxidative Stress in Parkinson’s Disease

Chang, K., & Chen, C. (2020) · Antioxidants · doi:10.3390/antiox9070597 · Cited by 357 · see citing works

Melatonin and mitochondrial function

León, J., Acuña-Castroviejo, D., Sainz, R. M., Mayo, J. C., Tan, D., & Reiter, R. J. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.03.003 · Cited by 331 · see citing works

Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases

Alexi, T. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00032-5 · Cited by 290 · see citing works

Mitochondrial Approaches for Neuroprotection

Chaturvedi, R. K., & Beal, M. F. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.027 · Cited by 294 · see citing works

Neurodegeneration and neuroprotection in Parkinson disease

Fahn, S., & Sulzer, D. L. (2004) · Neurotherapeutics · doi:10.1602/neurorx.1.1.139 · Cited by 266 · see citing works

Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice

Beal, M. F., Matthews, R. T., Tieleman, A., & Shults, C. W. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01192-x · Cited by 256 · see citing works

Mitochondrial Mechanisms of Neural Cell Death and Neuroprotective Interventions in Parkinson's Disease

Fiskum, G. M., Starkov, A. A., Polster, B. M., & Chinopoulos, C. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07469.x · Cited by 252 · see citing works

Antioxidants as treatment for neurodegenerative disorders

Moosmann, B., & Behl, C. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.10.1407 · Cited by 253 · see citing works

Calcium homeostasis, selective vulnerability and Parkinson's disease

Chan, C. S., Gertler, T. S., & Surmeier, D. J. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.01.006 · Cited by 239 · see citing works

The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease

Surmeier, D. J., Guzman, J. N., Sanchez-Padilla, J., & Schumacker, P. T. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.045 · Cited by 236 · see citing works

Bioenergetic approaches for neuroprotection in Parkinson's disease

Beal, M. F. (2003) · Annals of Neurology · doi:10.1002/ana.10479 · Cited by 236 · see citing works

Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III

Kaufmann, P., Thompson, J. L. P., Levy, G., Buchsbaum, R., Shefner, J. M., Krivickas, L. S., Katz, J., Rollins, Y. D., Barohn, R. J., Jackson, C. E., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21743 · Cited by 236 · see citing works

Combination therapy with Coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson’s and Huntington’s Diseases

Yang, L., Calingasan, N. Y., Wille, E. J., Cormier, K., Smith, K., Ferrante, R. J., & Beal, M. F. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06074.x · Cited by 232 · see citing works

Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease

Surmeier, D. J., Guzmán, J. N., & Sánchez-Padilla, J. (2010) · Cell Calcium · doi:10.1016/j.ceca.2009.12.003 · Cited by 221 · see citing works

A randomized clinical trial of coenzyme Q 10 and GPI-1485 in early Parkinson disease

The NINDS NET-PD Investigators (2007) · Neurology · doi:10.1212/01.wnl.0000250355.28474.8e · Cited by 219 · see citing works

Glutathione and Parkinson's disease: Is this the elephant in the room?

Zeevalk, G. D., Razmpour, R., & Bernard, L. P. (2008) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2008.01.017 · Cited by 209 · see citing works

Suboptimal medication adherence in Parkinson's disease

Grosset, K. A., Bone, I., & Grosset, D. G. (2005) · Movement Disorders · doi:10.1002/mds.20602 · Cited by 206 · see citing works

Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease

Müller, T. H., Büttner, T., Gholipour, A.-F., & Kuhn, W. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00185-x · Cited by 203 · see citing works

Coenzyme Q10 Deficiency and Response to Supplementation in Pediatric and Adolescent Migraine

Hershey, A. D., Powers, S. W., Vockell, A.-L. B., LeCates, S. L., Ellinor, P. L., Segers, A. M., Burdine, D., Manning, P., & Kabbouche, M. A. (2007) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2007.00652.x · Cited by 197 · see citing works

Progress in Parkinson's disease—Where do we stand?

Toulouse, A., & Sullivan, A. M. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.05.003 · Cited by 194 · see citing works

Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model

Ghosh, A., Chandran, K., Kalivendi, S. V., Joseph, J., Antholine, W. E., Hillard, C. J., Kanthasamy, A., Kanthasamy, A. G., & Kalyanaraman, B. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.08.028 · Cited by 191 · see citing works

A53T Human α-Synuclein Overexpression in Transgenic Mice Induces Pervasive Mitochondria Macroautophagy Defects Preceding Dopamine Neuron Degeneration

Chen, L., Xie, Z., Turkson, S., & Zhuang, X. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0089-14.2015 · Cited by 185 · see citing works

Coenzyme Q10 effects in neurodegenerative disease

Henchcliffe, C. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s5212 · Cited by 188 · see citing works

Safety assessment of coenzyme Q 10 (CoQ 10 )

Hidaka, T., Fujii, K., Funahashi, I., Fukutomi, N., & Hosoe, K. (2008) · BioFactors · doi:10.1002/biof.5520320124 · Cited by 187 · see citing works

Mitophagy and Oxidative Stress: The Role of Aging

Gaetano, A. D., Gibellini, L., Zanini, G., Nasi, M., Cossarizza, A., & Pinti, M. (2021) · Antioxidants · doi:10.3390/antiox10050794 · Cited by 188 · see citing works

Neuroprotective effects of the antiparkinson drug Mucuna pruriens

Manyam, B. V., Dhanasekaran, M., & Hare, T. A. (2004) · Phytotherapy Research · doi:10.1002/ptr.1514 · Cited by 185 · see citing works

Coenzyme Q10 Inhibits Glutamate Excitotoxicity and Oxidative Stress–Mediated Mitochondrial Alteration in a Mouse Model of Glaucoma

Lee, D.-W., Shim, M. S., Keun-young Kim, A., Noh, Y. H., Kim, H., Kim, S. Y., Weinreb, R. N., & Ju, W. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-12564 · Cited by 182 · see citing works

Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses

Morris, G., Berk, M., Walder, K. R., & Maes, M. H. J. (2015) · BMC Medicine · doi:10.1186/s12916-014-0259-2 · Cited by 179 · see citing works

Clinical Pharmacology of Rasagiline: A Novel, Second‐Generation Propargylamine for the Treatment of Parkinson Disease

Chen, J. J., & Swope, D. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005277935 · Cited by 179 · see citing works

Timing of treatment initiation in Parkinson's disease: A need for reappraisal?

Schapira, A. H. V., & Obeso, J. A. (2006) · Annals of Neurology · doi:10.1002/ana.20789 · Cited by 177 · see citing works

AMP Kinase Activation Mitigates Dopaminergic Dysfunction and Mitochondrial Abnormalities inDrosophilaModels of Parkinson's Disease

Ng, C.-H., Guan, M. S. H., Koh, C., Ouyang, X., Yu, F., Tan, E., O’Neill, S., Zhang, X., Chung, J., & Lim, K. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.0499-12.2012 · Cited by 177 · see citing works

Mitochondrial Dysfunction in Parkinson's Disease

Keane, P. C., Kurzawa‐Akanbi, M., Blain, P. G., & Morris, C. M. (2011) · Parkinson s Disease · doi:10.4061/2011/716871 · Cited by 177 · see citing works

Mitochondrial membrane depolarization and the selective death of dopaminergic neurons by rotenone: protective effect of coenzyme Q₁₀

Moon, Y., Lee, K. H., Park, J., Geum, D., & Kim, K. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03112.x · Cited by 174 · see citing works

Insights on the interaction of alpha-synuclein and metals in the pathophysiology of Parkinson's disease

Carboni, E., & Lingor, P. (2015) · Metallomics · doi:10.1039/c4mt00339j · Cited by 167 · see citing works

Metal‐Catalyzed Disruption of Membrane Protein and Lipid Signaling in the Pathogenesis of Neurodegenerative Disorders

Mattson, M. P. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.004 · Cited by 162 · see citing works

Therapeutic effects of coenzyme Q 10 (CoQ 10 ) and reduced CoQ 10 in the MPTP model of Parkinsonism

Cléren, C., Yang, L., Lorenzo, B. J., Calingasan, N. Y., Schomer, A. C., Sireci, A. N., Wille, E. J., & Beal, M. F. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05097.x · Cited by 158 · see citing works

Coenzyme Q 10 as a Possible Treatment for Neurodegenerative Diseases

Beal, M. F. (2002) · Free Radical Research · doi:10.1080/10715760290021315 · Cited by 160 · see citing works

Parkinson's disease-associated human ATP13A2 (PARK9) deficiency causes zinc dyshomeostasis and mitochondrial dysfunction

Park, J.-S., Koentjoro, B., Veivers, D., Mackay‐Sim, A., & Sue, C. M. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt623 · Cited by 156 · see citing works

Qigong exercise for the symptoms of Parkinson's disease: A randomized, controlled pilot study

Schmitz‐Hübsch, T., Pyfer, D., Kielwein, K., Fimmers, R., Klockgether, T., & Wüllner, U. (2005) · Movement Disorders · doi:10.1002/mds.20705 · Cited by 155 · see citing works

Coenzyme Q10 Therapy

Garrido‐Maraver, J., Cordero, M. D., Oropesa-Ávila, M., Fernández-Vega, A., de la Mata, M., Pavón, A. D., de Miguel, M., Calero, C. P., Paz, M. V., Cotán, D., et al. (2014) · Molecular Syndromology · doi:10.1159/000360101 · Cited by 154 · see citing works

Platelet bioenergetic screen in sickle cell patients reveals mitochondrial complex V inhibition, which contributes to platelet activation

Cárdenes, N., Corey, C. G., Geary, L., Jain, S., Zharikov, S. I., Barge, S., Novelli, E. M., & Shiva, S. (2014) · Blood · doi:10.1182/blood-2013-09-529420 · Cited by 148 · see citing works

Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease

Faust, K., Gehrke, S., Yang, Y., Yang, L., Beal, M. F., & Lu, B. (2009) · BMC Neuroscience · doi:10.1186/1471-2202-10-109 · Cited by 151 · see citing works

Feeding mitochondria: Potential role of nutritional components to improve critical illness convalescence

Wesselink, E., Koekkoek, W. A. C., Grefte, S., Witkamp, R. F., & van Zanten, A. R. H. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2018.08.032 · Cited by 146 · see citing works

Progress on the Mitochondrial Permeability Transition Pore: Regulation by Complex I and Ubiquinone Analogs

Fontaine, E. M., & Bernardi, P. (1999) · Journal of Bioenergetics and Biomembranes · doi:10.1023/a:1005475802350 · Cited by 146 · see citing works

Inhibition of oxidative stress by coenzyme Q10 increases mitochondrial mass and improves bioenergetic function in optic nerve head astrocytes

Noh, Y. H., Kim, K., Shim, M. S., Choi, S.-H., Choi, S., Ellisman, M. H., Weinreb, R. N., Perkins, G. A., & Ju, W.-K. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.341 · Cited by 146 · see citing works

Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease

Sohmiya, M., Tanaka, M., Wei Tak, N., Yanagisawa, M., Tanino, Y., Suzuki, Y., Okamoto, K., & Yamamoto, Y. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.05.007 · Cited by 143 · see citing works

The Origins of Oxidant Stress in Parkinson's Disease and Therapeutic Strategies

Surmeier, D. J., Guzmán, J. N., Sánchez-Padilla, J., & Goldberg, J. A. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3521 · Cited by 138 · see citing works

Therapeutic prospects for Parkinson disease

Olanow, C. W., & Schapira, A. H. V. (2013) · Annals of Neurology · doi:10.1002/ana.24011 · Cited by 140 · see citing works

The Promise of Neuroprotective Agents in Parkinson?s Disease

Seidl, S. E., & Potashkin, J. A. (2011) · Frontiers in Neurology · doi:10.3389/fneur.2011.00068 · Cited by 141 · see citing works

Review: Familial Parkinson's disease – genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease

Schiesling, C., Kieper, N., Seidel, K., & Krüger, R. (2008) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2008.00952.x · Cited by 135 · see citing works

A randomized trial of coenzyme Q 10 in mitochondrial disorders

Glover, E. I., Martin, J. C., Maher, A. C., Thornhill, R. E., Moran, G. R., & Tarnopolsky, M. A. (2010) · Muscle & Nerve · doi:10.1002/mus.21758 · Cited by 137 · see citing works

Oxidative Stress Involvement in α -Synuclein Oligomerization in Parkinson's Disease Cybrids

Esteves, A. R., Arduíno, D. M., Swerdlow, R. H., Oliveira, C. R., & Cardoso, S. M. (2008) · Antioxidants and Redox Signaling · doi:10.1089/ars.2008.2247 · Cited by 137 · see citing works

Mitochondrial alterations in Parkinson’s disease: new clues

Vila, M., Ramonet, D., & Perier, C. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05604.x · Cited by 131 · see citing works

Levels of reduced and oxidized coenzymeQ-10 and 8-hydroxy-2′-deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson's disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process

Isobe, C., Abe, T., & Terayama, Y. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.11.065 · Cited by 130 · see citing works

Is coenzyme Q a key factor in aging?

López‐Lluch, G., Rodríguez‐Aguilera, J. C., Santos‐Ocaña, C., & Navas, P. (2010) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2010.02.003 · Cited by 129 · see citing works

Mitochondrial DNA analysis: polymorphisms and pathogenicity

Chinnery, P. F., Howell, N., Andrews, R. M., & Turnbull, D. M. (1999) · Journal of Medical Genetics · doi:10.1136/jmg.36.7.505 · Cited by 128 · see citing works

Control of Reactive Oxygen Species for the Prevention of Parkinson’s Disease: The Possible Application of Flavonoids

Kim, T. Y., Leem, E., Lee, J. M., & Kim, S. R. (2020) · Antioxidants · doi:10.3390/antiox9070583 · Cited by 128 · see citing works

An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition

Members, E. W. E., Terron, A., Bal-Price, A., Paini, A., Monnet-Tschudi, F., Bennekou, S. H., Leist, M., & Schildknecht, S. (2018) · Archives of Toxicology · doi:10.1007/s00204-017-2133-4 · Cited by 124 · see citing works

Tissue transglutaminase catalyzes the formation of alpha‐synuclein crosslinks in Parkinson's disease

Andringa, G., Lam, K., Chegary, M., Wang, X., Chase, T. N., & Bennett, M. C. (2004) · The FASEB Journal · doi:10.1096/fj.03-0829fje · Cited by 123 · see citing works

Mitochondrial dysfunction and amyotrophic lateral sclerosis

Hervías, I., Beal, M. F., & Manfredi, G. (2005) · Muscle & Nerve · doi:10.1002/mus.20489 · Cited by 122 · see citing works

Physiological Phenotype and Vulnerability in Parkinson's DiseasePreprint

Surmeier, D. J., Guzmán, J. N., Sánchez, J. A., & Schumacker, P. T. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009290 · Cited by 115 · see citing works

Coenzyme Q Induces Nigral Mitochondrial Uncoupling and Prevents Dopamine Cell Loss in a Primate Model of Parkinson’s Disease

Horváth, T. L., Diano, S., Léránth, C., García‐Segura, L. M., Cowley, M. A., Shanabrough, M., Elsworth, J. D., Sótonyi, P., Roth, R. H., Dietrich, E. H., et al. (2003) · Endocrinology · doi:10.1210/en.2003-0163 · Cited by 116 · see citing works

Coenzyme Q10administration and its potential for treatment of neurodegenerative diseases

Beal, M. F. (1999) · BioFactors · doi:10.1002/biof.5520090222 · Cited by 111 · see citing works

Parkinson's disease as multifactorial oxidative neurodegeneration: implications for integrative management.

Kidd, P. M. (2000) · PubMed · Cited by 110 · see citing works

Anti-Oxidants in Parkinson's Disease Therapy: A Critical Point of View

Filograna, R., Beltramini, M., Bubacco, L., & Bisaglia, M. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666151030102718 · Cited by 110 · see citing works

The Roles of Coenzyme Q in Disease: Direct and Indirect Involvement in Cellular Functions

Pallotti, F., Bergamini, C., Lamperti, C., & Fato, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010128 · Cited by 109 · see citing works

Genetic Insights into Sporadic Parkinson's Disease Pathogenesis

Chai, C., & Lim, K. (2014) · Current Genomics · doi:10.2174/1389202914666131210195808 · Cited by 108 · see citing works

The Centrality of Mitochondria in the Pathogenesis and Treatment of Parkinson's Disease

Camilleri, A., & Vassallo, N. (2014) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12264 · Cited by 104 · see citing works

Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease

Beal, M. F. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70812-0 · Cited by 103 · see citing works

Mitochondrial dysfunction and Parkinson disease: a Parkin–AMPK alliance in neuroprotection

Hang, L., Thundyil, J., & Lim, K. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12820 · Cited by 101 · see citing works

Clinical measures of progression in Parkinson's disease

Poewe, W. H. (2009) · Movement Disorders · doi:10.1002/mds.22600 · Cited by 98 · see citing works

Coenzyme Q10:A Review of Its Promise as a Neuroprotectant

Young, A. J., Johnson, S., Steffens, D. C., & Doraiswamy, P. M. (2007) · CNS Spectrums · doi:10.1017/s1092852900020538 · Cited by 97 · see citing works

Coenzyme Q10 Depletion in Medical and Neuropsychiatric Disorders: Potential Repercussions and Therapeutic Implications

Morris, G., Anderson, G., Berk, M., & Maes, M. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8477-8 · Cited by 96 · see citing works

Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson's disease and catecholamine‐associated diseases

Gluck, M. R., & Zeevalk, G. D. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02747.x · Cited by 96 · see citing works

α-Tocotrienol quinone modulates oxidative stress response and the biochemistry of aging

Shrader, W. D., Amagata, A., Barnes, A. J., Enns, G. M., Hinman, A., Jankowski, O. D., Kheifets, V., Komatsuzaki, R., Lee, E., Mollard, P., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.04.085 · Cited by 96 · see citing works

Glutamate and Mitochondria: Two Prominent Players in the Oxidative Stress-Induced Neurodegeneration

Cassano, T., Pace, L., Bedse, G., Lavecchia, A. M., Marco, F. D., Gaetani, S., & Serviddio, G. (2015) · Current Alzheimer Research · doi:10.2174/1567205013666151218132725 · Cited by 95 · see citing works

High doses of nicotinamide prevent oxidative mitochondrial dysfunction in a cellular model and improve motor deficit in a Drosophila model of Parkinson's disease

Jia, H., Li, X., Gao, H., Feng, Z., Li, X., Zhao, L., Jia, X., Zhang, H., & Liu, J. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21650 · Cited by 98 · see citing works

Cellular Consequences of Coenzyme Q10 Deficiency in Neurodegeneration of the Retina and Brain

Manzar, H., Abdulhussein, D., Yap, T. E., & Cordeiro, M. F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239299 · Cited by 94 · see citing works

Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease

Yoritaka, A., Kawajiri, S., Yamamoto, Y., Nakahara, T., Ando, M., Hashimoto, K., Nagase, M., Saito, Y., & Hattori, N. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.05.022 · Cited by 94 · see citing works

Medicine‐taking behavior: Implications of suboptimal compliance in Parkinson's disease

Grosset, K. A., Reid, J. L., & Grosset, D. G. (2005) · Movement Disorders · doi:10.1002/mds.20525 · Cited by 92 · see citing works

Altered redox state of platelet coenzyme Q 10 in Parkinson's disease

Götz, M. E., Gerstner, A., Harth, R., Dirr, A., Janetzky, B., Kuhn, W., Riederer, P., & Gerlach, M. (2000) · Journal of Neural Transmission · doi:10.1007/s007020050003 · Cited by 93 · see citing works

Coenzyme Q₁₀: From bench to clinic in aging diseases, a translational review

Gutierrez-Mariscal, F. M., Yubero-Serrano, E. M., Villalba, J. M., & Lopez-Miranda, J. (2019) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1442316 · Cited by 92 · see citing works

A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease

Shults, C. W., Haas, R., & Beal, M. F. (1999) · BioFactors · doi:10.1002/biof.5520090223 · Cited by 91 · see citing works

Nrf2 Pathway in Age-Related Neurological Disorders: Insights into MicroRNAs

Paladino, S., Conte, A., Caggiano, R., Pierantoni, G. M., & Faraonio, R. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000491465 · Cited by 92 · see citing works

Safety and tolerability of high‐dosage coenzyme Q10 in Huntington's disease and healthy subjects

The Huntington Study Group Pre2CARE Investigators (2010) · Movement Disorders · doi:10.1002/mds.22408 · Cited by 91 · see citing works

Nutrients to Improve Mitochondrial Function to Reduce Brain Energy Deficit and Oxidative Stress in Migraine

Fila, M., Chojnacki, C. J., Chojnacki, J., & Błasiak, J. (2021) · Nutrients · doi:10.3390/nu13124433 · Cited by 89 · see citing works

A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease

Shults, C. W., Haas, R., & Beal, M. F. (1999) · BioFactors · doi:10.1002/biof.5520090223 · Cited by 91 · see citing works

Altered redox state of platelet coenzyme Q 10 in Parkinson's disease

Götz, M. E., Gerstner, A., Harth, R., Dirr, A., Janetzky, B., Kuhn, W., Riederer, P., & Gerlach, M. (2000) · Journal of Neural Transmission · doi:10.1007/s007020050003 · Cited by 93 · see citing works

Complex-1 activity and 18F-DOPA uptake in genetically engineered mouse model of Parkinson's disease and the neuroprotective role of coenzyme Q10

SHARMA, S. K., Refaey, H. E., & Ebadi, M. (2005) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2005.11.019 · Cited by 56 · see citing works

Therapeutic role of coenzyme Q10 in Parkinson's disease

Shults, C. W. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.02.002 · Cited by 76 · see citing works

Coenzyme Q10 shows promise for PD

Love, R. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(02)00246-6 · Cited by 1 · see citing works